Back to top

Image: Bigstock

Dr. Reddy's Laboratories Ltd.

Read MoreHide Full Article

Dr. Reddy’s top and bottom line suffered a year-over-year decline in fourth-quarter fiscal 2018 primarily due to continuing headwinds in the U.S.  markets and a temporary drop in sales in Russia in the fourth quarter as a result of the shift in thechannel purchasing pattern. Going forward, the company plans to continue to work diligently on resolving pending regulatory issues. The company’s shares have underperformed the industry year to date. However, the company will also focus on accelerating new products to market and improving its approval process. Dr. Reddy’s is undertaking some strategic measures to combat the challenges. The company also enjoys a strong position in the generics market.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Dr. Reddys Laboratories Ltd (RDY) - free report >>

Published in